{
    "clinical_study": {
        "@rank": "77451", 
        "brief_summary": {
            "textblock": "To determine whether acute ionized hypomagnesemia and hypocalcemia immediately following\n      foscarnet infusions can be lessened or eliminated by prior infusion of magnesium sulfate. To\n      determine whether reductions in ionized magnesium, ionized calcium, and parathyroid hormone\n      levels following foscarnet infusions are lessened by preinfusion of magnesium sulfate. To\n      evaluate the safety of intravenous magnesium sulfate prior to foscarnet infusion by\n      monitoring blood pressure, heart rate, and heart rhythm. To characterize the effect of\n      magnesium sulfate on foscarnet blood levels and urinary excretion of calcium, magnesium,\n      phosphate, and foscarnet."
        }, 
        "brief_title": "Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study", 
        "condition": [
            "Cytomegalovirus Infections", 
            "HIV Infections", 
            "Hypocalcemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Cytomegalovirus Infections", 
                "Hypocalcemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to one of four treatment groups. Intravenous foscarnet is\n      administered for 4 days. Patients receive one of three doses of magnesium sulfate or placebo\n      in normal saline according to one of four schedules. Sequence of doses will differ for each\n      group."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  AIDS by CDC criteria.\n\n          -  Documented CMV disease.\n\n          -  Tolerance of foscarnet dose of 90 mg/kg bid.\n\n          -  Normal serum calcium, serum creatinine, and serum phosphate.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Known allergy to Foscarnet.\n\n          -  In extremis or incapacitated because of underlying illness (e.g., comatose or\n             tracheally intubated).\n\n          -  Volume depletion.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Nephrotoxic drugs such as IV pentamidine, amphotericin B, aminoglycosides, and\n             cisplatin.\n\n          -  Other investigational drugs that affect metabolic balance, such as human growth\n             hormone.\n\n          -  Oral or parenteral magnesium and calcium supplementation.\n\n        Patients with the following prior condition are excluded:\n\n        History of heart block."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "12", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002146", 
            "org_study_id": "020J", 
            "secondary_id": "94-FOS-32"
        }, 
        "intervention": [
            {
                "intervention_name": "Magnesium sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Foscarnet sodium", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Foscarnet", 
                "Phosphonoacetic Acid", 
                "Magnesium Sulfate"
            ]
        }, 
        "keyword": [
            "Infusions, Intravenous", 
            "Foscarnet", 
            "Cytomegalovirus Infections", 
            "Acquired Immunodeficiency Syndrome", 
            "Magnesium Sulfate", 
            "Magnesium Deficiency", 
            "Hypocalcemia"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Oklahoma City", 
                    "country": "United States", 
                    "state": "Oklahoma", 
                    "zip": "731045028"
                }, 
                "name": "Oklahoma City Veterans Administration Med Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002146"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astra USA", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 1997"
    }, 
    "geocoordinates": {
        "Oklahoma City Veterans Administration Med Ctr": "35.468 -97.516"
    }
}